Adjuvant chemotherapy may not be the best option for patients with certain subtypes of breast cancer who show no clear benefit, according to an extensive retrospective of four clinical trials published June 12 in Breast Cancer Research and Treatment.

Radioimmunotherapy with Lu-177 DOTA-rituximab represents a novel and well-matched treatment for B-cell Lymphoma, but no consensus on standardized dosimetry was available, until now, according to research published in the July issue of Journal of Nuclear Medicine.

Personalized therapy assessment for Hodgkin lymphoma (HL) with interim FDG PET could help step up or step down treatment to find the curative sweet spot, but the transition from PET-adaptive clinical trials to practice requires additional time to prove broad benefit for patients, according to a review published July 1 in the Journal of Nuclear Medicine.

The Centers for Medicare & Medicaid Services (CMS) has released its draft decision for coverage of amyloid PET imaging for the evaluation of dementia and neurodegenerative diseases, including Alzheimer’s. CMS is proposing coverage with evidence development (CED) as of the July 3 memo, which allows one scan to rule out Alzheimer’s pathology in the brain for patients in eligible clinical trials and it would require clinicians to provide detailed data about amyloid PET imaging to gather a body of evidence to make the case for reimbursement of procedures in this category.

For patients who have just suffered myocardial infarction due to CAD and heart failure, gleaning information about left ventricular (LV) viability with gated blood-pool imaging is highly recommended. Dedicated cardiac SPECT cameras with state-of-the-art detectors and image processing offer a new alternative that may provide advantages compared with traditional SPECT systems. 

Royal Philips has received 510(k) clearance from the FDA to market its AlluraClarity live image guidance system in the United States.

As the National Weather Service issued its predictions for where and when Hurricane Sandy would the Atlantic states in late October of last year, John McCabe, product service director for MR at GE Healthcare and his colleagues watched closely

A connection between cerebral blood volume (CBV) and tumor metabolism in 3D PET and MR characterized a range of pediatric brain tumors. The two modalities were found to sync complementary functional and metabolic information in 94 percent of cases and could have an impact on risk stratification and prognosis with further study, according to research published June 25 in the Journal of Nuclear Medicine.